ESALF - Merck/Eisai's Keytruda and Lenvima combo meet endpoints in late-stage uterine cancer study

Merck (MRK) and Eisai (ESALF) have announced data demonstrating positive top-line results from Phase 3 KEYNOTE-775/Study 309, evaluating Merck's Keytruda plus Eisai's Lenvima in patients with advanced endometrial cancer following at least one prior platinum-based regimen.The study met its primary and secondary endpoints, and demonstrated a statistically significant and clinically meaningful improvement in overall survival, progression-free survival and objective response rate versus chemotherapy (treatment of physician’s choice of doxorubicin or paclitaxel).Safety profile of drug combination was consistent with previously reported studies.Merck and Eisai will discuss these data with regulatory authorities, with the intent to submit marketing authorization applications, and plan to present these results at an upcoming medical meeting.Earlier today, BioLineRx's motixafortide and Keytruda combination trial reported median OS of 6.5 months compared to historical data of 4.7 months in pancreatic cancer.Last month, both the companies also announced that Keytruda plus Lenvima combination met endpoints in advanced renal cell carcinoma study.

For further details see:

Merck/Eisai's Keytruda and Lenvima combo meet endpoints in late-stage uterine cancer study